Yahoo · Aug 14, 2026
Altria Rises 13% YTD: Should You Buy, Sell or Hold the Stock?
MO gains 12.8% YTD as smoke-free growth and pricing support earnings, but cigarette declines and oral tobacco weakness temper the outlook.

NYSE · PM
Consumer Defensive · Tobacco
$188.91
Up+$1.48 (+0.78%)
Updated Aug 15, 2026, 1:11 AM
SID Score
7.6/10
Composite research score
Smart Money
62/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
PM closed at $188.91 after 20 trading sessions, down 2.11% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 13, 2026 | $187.93 | $191.435 | $187.20 | $188.91 | 3.35M |
| Aug 12, 2026 | $184.28 | $187.00 | $184.0221 | $186.19 | 3.54M |
| Aug 11, 2026 | $185.11 | $187.2951 | $184.71 | $186.22 | 3.47M |
| Aug 10, 2026 | $188.00 | $188.60 | $185.01 | $186.00 | 3.15M |
| Aug 7, 2026 | $187.28 | $190.17 | $186.51 | $189.57 | 4.72M |
| Aug 6, 2026 | $191.15 | $191.54 | $186.66 | $188.05 | 5.64M |
| Aug 5, 2026 | $188.31 | $190.3575 | $185.50 | $188.93 | 5.54M |
| Aug 4, 2026 | $186.00 | $187.46 | $184.36 | $186.91 | 5.39M |
| Aug 3, 2026 | $192.40 | $192.68 | $187.34 | $187.41 | 3.99M |
| Jul 31, 2026 | $190.08 | $193.46 | $188.9468 | $190.82 | 5.45M |
| Jul 30, 2026 | $193.20 | $195.92 | $191.67 | $192.00 | 6.8M |
| Jul 29, 2026 | $201.00 | $202.57 | $198.19 | $198.44 | 3.92M |
| Jul 28, 2026 | $198.76 | $207.76 | $198.68 | $200.17 | 8.07M |
| Jul 27, 2026 | $193.00 | $196.79 | $192.55 | $195.66 | 3.7M |
| Jul 24, 2026 | $192.59 | $195.625 | $191.7801 | $193.00 | 4.44M |
| Jul 23, 2026 | $191.95 | $194.72 | $189.0518 | $191.12 | 6.45M |
| Jul 22, 2026 | $192.03 | $199.78 | $189.38 | $194.30 | 7.8M |
| Jul 21, 2026 | $191.80 | $193.00 | $187.31 | $188.04 | 6.51M |
| Jul 20, 2026 | $192.80 | $194.90 | $191.16 | $192.72 | 4.75M |
| Jul 17, 2026 | $191.99 | $194.62 | $190.60 | $192.98 | 5.2M |
The latest Smart Investors Daily articles mentioning PM.
PM research
Company profile and research snapshot.
Created from the international operations of Altria in 2008, Philip Morris International sells cigarettes and reduced-risk products, including heat sticks, vapes, and oral nicotine offerings, primarily outside of the US. With the 2023 acquisition of Swedish Match, a leading manufacturer of traditional oral tobacco products and nicotine pouches primarily in the US and Scandinavia, PMI is not only dominant in smokable products but also has the Iqos and Zyn brands, which respectively dominate heated tobacco and nicotine pouches in most markets.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 30, 2026 | Citigroup | Buy | — |
| Jul 29, 2026 | Barclays | Overweight | — |
| Jul 23, 2026 | Morgan Stanley | Overweight | — |
| Jul 23, 2026 | Stifel | Buy | — |
| Jul 23, 2026 | Needham | Buy | — |
No generated briefing is available yet.
Yahoo · Aug 14, 2026
MO gains 12.8% YTD as smoke-free growth and pricing support earnings, but cigarette declines and oral tobacco weakness temper the outlook.
Yahoo · Aug 11, 2026
High-yield ETFs built purely on yield rankings carry a hidden flaw that only shows up when it's too late, and one fund uses a decade-long dividend track record as a filter before yield ever enters the picture.
Yahoo · Aug 10, 2026
“Too big to fail” is how we would describe the megacap stocks in this article today. While they will likely stand the test of time, it’s not all sunshine and rainbows as their scale can limit their ability to find new sources of growth.
Yahoo · Aug 10, 2026
Universal Corp just cratered to a fresh 52-week low while rival tobacco stocks barely flinched, raising an urgent question about whether this leaf tobacco supplier is facing a problem all its own.
Interpretive context generated from the platform’s current data sources.
Philip Morris International Inc. shares traded at $188.91, reflecting a daily decline of 0.73%, per SID market data. Over the trailing one-month period, PM gained 5.82%, though the three-month return turned slightly negative at -0.4%. The stock delivered a robust 23.26% return over the past twelve months, underscoring sustained investor interest in the consumer defensive sector. Technically, PM trades above both its 50-day moving average of $184.42 and its 200-day moving average of $176.40, confirming an intact longer-term uptrend according to Massive/Polygon data. However, the 14-day RSI reads 41.9, placing the stock in neutral-to-slightly-oversold territory after recent pullback activity. PM carries a beta of 0.436, indicating significantly lower volatility than the broader market. Average daily trading volume stands at approximately 6.58 million shares, supporting adequate liquidity for institutional positioning. The current market capitalization is approximately $234.96 billion.
Philip Morris International trades at a price-to-earnings ratio of 27.29, a premium relative to many consumer defensive peers, according to SID market data. The PEG ratio stands at 5.76, suggesting the current earnings multiple is elevated relative to the company's projected earnings growth rate. PM's dividend yield is 3.66%, providing meaningful income for shareholders, per SEC filings. Notably, the price-to-book ratio registers at negative 21.53, a consequence of Philip Morris carrying negative shareholders' equity on its balance sheet — a structural feature common among companies with extensive share buyback programs and significant accumulated goodwill write-downs. This negative book value means traditional price-to-book comparisons are not applicable for PM. The combination of a high PEG ratio and premium P/E multiple indicates the market is pricing in expectations for sustained revenue growth from reduced-risk products such as IQOS and ZYN nicotine pouches, which have become central to the company's long-term strategy.
Philip Morris International carries an overall smart money score of 62 out of 100 with a neutral signal, according to SID market data. Institutional activity represents the strongest component, scoring a perfect 25 out of 25, indicating heavy and consistent accumulation by large fund managers per 13F institutional filings. Insider activity scores 12.5 out of 25, reflecting a moderate level of executive and director transactions without a decisive directional bias according to SEC Form 4 filings. Dark pool activity registers at 12.5 out of 25, suggesting that off-exchange block trading volume has been balanced between buyers and sellers in recent periods. Congressional trading activity scores 12 out of 25, indicating limited but present legislative member interest in PM shares. The divergence between maximum institutional conviction and more muted insider participation suggests that large asset managers remain confident in the company's trajectory while corporate insiders have neither aggressively accumulated nor meaningfully reduced their positions in recent filing periods.
Philip Morris International has demonstrated a consistent pattern of exceeding analyst expectations across its most recent quarterly results, per company earnings reports. In the most recently reported quarter, PM posted earnings per share of $2.20 against a consensus estimate of $2.05, representing a positive surprise of $0.15 or approximately 7.3%. The prior quarter saw EPS of $1.96 versus estimates of $1.82, another beat of $0.14. The quarter before that produced a narrower upside surprise, with actual EPS of $1.70 compared to the $1.69 estimate. Looking ahead, analysts project EPS of $2.05 for the upcoming quarter, according to consensus analyst estimates. The sequential earnings trajectory — from $1.70 to $1.96 to $2.20 — illustrates meaningful quarter-over-quarter growth, potentially driven by expanding heated tobacco and oral nicotine product volumes. The next earnings report is scheduled for July 21, 2026.
Wall Street consensus on Philip Morris International remains uniformly bullish, with all five most recent analyst actions reiterating positive ratings, per Wall Street analyst reports. On July 30, 2026, Citigroup maintained its Buy rating on PM shares. Barclays reiterated its Overweight stance on July 29, while Morgan Stanley also maintained Overweight on July 23. Stifel and Needham both reaffirmed Buy ratings on July 23 as well, according to SID consensus data. Notably, none of these actions represented upgrades; each analyst maintained a previously established positive outlook, suggesting that recent earnings results reinforced rather than changed existing bullish theses. The clustering of reiterations around the late July period aligns with the company's quarterly earnings release on July 22, indicating that PM's reported $2.20 EPS — exceeding the $2.05 consensus estimate — validated analyst expectations. The absence of any Hold or Sell ratings among recent coverage updates reflects broad institutional confidence in the company's growth strategy centered on reduced-risk products.


The latest Smart Investors Daily articles mentioning PM.